CALGB 140503 - A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (d 2 CM) Peripheral Non-Small Cell Lung Cancer
CALGB 30406 - Phase II Randomized Study of OSI-774 (ERLOTINIB) W/WO Carboplatin/Paclitaxel in Patients with Previously Untreated adenocarcinoma of the Lung Who Never Smoked or were Former Light Smokers
CALGB 30504 - Combination Cisplatin, Etoposide and Sunitinib for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/II Study
CALGB 30602 - A Phase Ii Study of Dasatinib (NSC #732517, IND #73969) In Patients with Chemo-Sensitive Relapsed Small Cell Lung Cancer
CALGB 30605 - A Phase II Study of Induction Chemotherapy Followed By Thoracic Radiotherapy and Erlotinib In Poor-Risk Stage III Non-Small Cell Lung Cancer
CALGB 30607 - Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
CALGB 30610 - Phase III Comparison of Thoracic Radiotherapy Regimens In Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
GCC 0532 - Phase 1-2a Dose-Ranging Study of the Triplet Combination of Carboplatin, Paclitaxel and TLK286 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
GCC 0615 - hase II Study Of Bortezomib (PS-341) For Patients With Advanced Bronchiolo-Alveolar Carcinoma (BAC) Or Adenocarcinoma With BAC Features
GCC 0616 - Phase 2 Study of AZD 2171 (NSC 732208) in Combination with Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS:10029514
GCC 0757 - (ECOG 1505) A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (4 cm or larger) - IIIA Non-Small Cell Lung Cancer (NSCLC)
GCC 0760 - A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-positive Non-Small Cell Lung Cancer
GCC 0793 - A Multicenter Phase III Randomized, Double-Blind Placebo-Controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
GCC 0822 - A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
GCC 0833 - Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects with Advanced Non-Small Cell Lung Cancer
GCC0761 - A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast And Non-Small Cell Lung (NSCLC) Cancers
NCCTG 0723 - MARVEL: Marker Validation of Erlotinib in Lung Cancer: A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
RTOG 0229 - A Phase II Trial of Neoadjuvant Therapy With Concurrent Chemotherapy and High Dose Radiotherapy Followed by Surgical Resection and Consolidative Therapy for Locally Advanced Non-Small Cell Lung Carcinoma
RTOG 0235 - ACRIN 6668 : Positron Emission Tomography Pre- and Post-Treatment Assessment for Locally Advanced Non-small Cell Lung Carcinoma
Email this Page
Print this Page
